Creative Dyax Buys Back Royalty Rights Through Better-Terms Cowen Loan
This article was originally published in The Pink Sheet Daily
Executive Summary
Italy’s Dompe Farmaceutici waiting for next month’s HAE data to decide on European deal.
You may also be interested in...
Dyax Restructures Royalty Loan Agreement, Bringing In $15 Million
Extension of royalty-sharing with Cowen Healthcare Royalty Partners enables Dyax to fund itself while awaiting FDA’s decision on ecallantide – but at a steep price.
Dyax Restructures Royalty Loan Agreement, Bringing In $15 Million
Extension of royalty-sharing with Cowen Healthcare Royalty Partners enables Dyax to fund itself while awaiting FDA’s decision on ecallantide – but at a steep price.
Cowen Royalty Buyers In “Right Place, Right Time”
Deal to purchase royalty stream from LifeCycle exemplifies what deal-makers want in tight equity market.